The OHSU Knight Cancer Institute is a pioneer in personalized cancer treatment and research, led by Dr. Brian Druker, whose development of Gleevec transformed Chronic Myeloid Leukemia from a fatal disease to a manageable one and proved that targeted therapies can work. The institute focuses on precision oncology, the early detection, prevention, and treatment of cancer, and creating a welcoming and supportive environment for its caregivers, researchers, and support personnel. Knight affiliates subscribe to three guiding principles: we are bold, we are supportive, and we work as a connected team in our fight to end cancer as we know it.
The primary mission of the Division of Oncological Sciences at OHSU's Knight Cancer Institute is to better understand cancer through basic, translational and population-based research that improves cancer prevention, detection and treatments for all. Our community of faculty, trainees and staff brings together scientists from a broad range of disciplines and works collaboratively to advance innovation and translate discoveries from the lab into meaningful impacts for cancer patients and our community. We’d love for you to join us!
Every Knight Cancer employee is expected to embody our guiding principles:
We act BOLDLY—Breakthroughs require pushing the boundaries of science, exploring new frontiers, and thinking differentlyWe SUPPORT each other—Respect leads to trust, which leads to excellenceWe work as a CONNECTED team — We must leverage our collective brain power to conquer cancer because no one individual can do it alone Function/Duties of PositionAn exciting opportunity has been created for an experienced researcher to join the Dr. Anupriya Agarwal Laboratory at the OHSU Knight Cancer Institute as an Senior Research Associate in Portland, OR to study the mechanisms of leukemia initiation and drug resistance using multi-omics approaches.
Dr. Agarwal and her team for over past 15 years focusing on identifying novel signaling pathways that are requisite for leukemia initiation, clonal evolution, and drug resistance. This position will be a hybrid between wet lab and computational disciplines, with a dedicated mentorship in both areas. The new team member will help lead the project focused on understanding the mechanisms of leukemia initiation and drug resistance in a context dependent manner. The project will use variety of advanced molecular biology techniques, CRISPR methods along with single cell transcriptomic, epigenetic, and genomic profiling in premalignant and malignant models using murine and human cells in vitro and in vivo. The candidate should also be able to perform complex data analysis, along with downstream analyses using computational approaches. Applicants will need to possess strong technical and organizational skills as well as the ability to manage an independent project.
A PhD and 1-2 years of post-graduate research experience in the relevant field is preferred. Laboratory and/or computational experience in the field of molecular/cellular biology, cancer biology or a related field is preferred. Experience with sequencing library preparation, epigenetics, flow cytometry, or murine models of disease would be especially beneficial. The ideal candidate would have deep expertise in a singular area of focus but may also have worked as boundary spanners across multiple fields. Salary will be commensurate with experience. Achieving this position requires that the researcher have demonstrated a satisfactory track record of scholarly activity including high-quality peer-reviewed publications. We are looking for an enthusiastic individual who is capable and willing to make maximum use of excellent facilities and a productive environment.
Relevant publications for the position are below:
Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz J, Borate U, Wilmot B, Tognon C, Bock AM, Pollyea DA, Radhakrishnan S, Radhakrishnan S, Patel P, Collins RH, Tantravahi S, Deininger MW, Fan G, Druker B, Shinde U, Tyner JW, Press RD, McWeeney S, Agarwal A*. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. Blood. 2022, 139(8): 1208-1221 PMC9211447, *Corresponding author. Prospective in ASH Clinical News, Selected for Podcast and Commentary in Blood 2022.Kurtz S, Eide CA, Kaempf A, Long N, Bottomly D, Nikolova O, Druker BJ, McWeeney SK, Tyner JW, Agarwal A. Associating Ex Vivo Drug Sensitivity with Differentiation Status Identifies Effective Drug Combinations for Acute Myeloid Leukemia. Blood Advances 2022, 6(10): 3062-3067. Hosseini MH, Kurtz SE, Abdelhamed S, Mahmood S, Davare, MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JK, Agarwal A. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. 2018, 32(11):2374-87. PMC6558520Carey A, Edwards D, Eide C A, Newell L, Traer E, Medeiros B, Pollyea DA, Deininger MW, Collins R, Tyner J W, Druker B J, Bagby G C, McWeeney S, Agarwal A*. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Reports. 2017, 18(13):3204-18. PMC5437102 Agarwal A, Bolosky BJ, Wilson DB, Eide CA, Olson SB, Fan G, Druker BJ. Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2019, 116(49):24593-24599. PMC690050. * Co-corresponding Author- Highlighted in “In This Issue PNAS”.Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A……. et al; Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia. Cancer Cell 2022, in press (collaborative manuscript) Required Qualifications PhD in relevant field AND 1 year of relevant experience OR Master's Degree in relevant field AND 5 years of relevant experience OR Bachelor's Degree in relevant field AND 9 years of relevant experience OR Equivalent combination of training and experienceProficient with computers specifically MS Office (which includes, Excel, Access, Word and PowerPoint) and statistical analysis softwareProficient with computers specifically MS Office (which includes, Excel, Access, Word and PowerPoint) and statistical analysis softwareExperience handling chemical and biologically hazardous materialsKnowledge of policy and regulations applicable to the laboratory, including but not limited to safety, animal and radiationTechnical proficiency, scientific creativity collaborative ability, and independent thinkerProven ability to work collaboratively with a high performing work groupAbility to prioritize multiple tasks at one timeMust have excellent communication, analytical and organizational skills: both written and verbalAbility to work independently and as part of a team while being collaborative in resolving problemsDemonstrated ability to learn new and innovative processed quicklyMust possess energy and drive to coordinate multiple projects simultaneouslyAbility to use tact and diplomacy to maintain effective working relationshipsAbility to operate complex scientific equipment and develop and troubleshoot complex experimental protocols Preferred Qualifications Masters in computational biologyExperience in both wet and computational field Additional DetailsApply online. Please be sure to upload a Cover Letter and Resume/CV.
We offer a variety of benefits on top of joining a thriving organization:
Medical, dental and vision coverage at no or low cost to employeesCovered 100% for full-time employees and 88% for dependentsSeveral retirement plans to choose from with contributions from OHSUUp to 208 hours (equal to 25 full days) a year of paid time offCommuter subsidiesTuition reimbursementAccess to group life insurance, disability insurance and other supplemental benefitsAnnual RaisesGrowth/Development OpportunitiesEmployee discounts to local and major businesses#linkedin #indeed #knightcancerjobs #knightresearchandlabjobs #knightresearchjobs